Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics announced significant progress in its clinical trials and corporate activities for the quarter ending December 2024. They dosed the first three patients in their Phase 1/2 CHM CDH17 CAR-T cell therapy trial, which targets difficult-to-treat gastrointestinal cancers. Additionally, a complete response was observed in an AML patient within a Phase 1B trial, and the company raised $5 million to support ongoing programs. With the appointment of Dr. Rebecca McQualter as CEO, Chimeric continues to strengthen its leadership and strategic direction.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian company specializing in cell therapy, focusing on developing innovative treatments for cancer. Their primary product is the CHM CDH17 CAR-T cell therapy, targeting gastrointestinal cancers, and they are conducting trials in the US.
Average Trading Volume: 3,586,849
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$9.45M
See more data about CHM stock on TipRanks’ Stock Analysis page.
